Working with interdisciplinary teams and nurse navigators to coordinate care across specialties is a facet of oncology nursing that may be overlooked, says an expert.

Experts discuss effective communication strategies for managing patient and caregiver expectations about treatment adverse ...

Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and ...

Experts discuss how to balance treatment intensity with maintaining quality of life, particularly in patients with advanced-stage disease.

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored. Toxicity may often be underreported in two-arm, ...

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark. The addition of ipilimumab (Yervoy) and ...

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for ...

Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at ...

What multidisciplinary strategies have you found effective in managing the range of side effects associated with ALK inhibitors?

In your experience, how does lorlatinib’s side effect profile compare to other ALK inhibitors? Are there unique challenges or benefits with lorlatinib?

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant ...